An Open Label Extension Study to Evaluate the Safety, Tolerability and Pharmacokinetics of STX209 in Subjects With Autism Spectrum Disorders [EXTENSION OF 700041825]

Trial Profile

An Open Label Extension Study to Evaluate the Safety, Tolerability and Pharmacokinetics of STX209 in Subjects With Autism Spectrum Disorders [EXTENSION OF 700041825]

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2013

At a glance

  • Drugs Arbaclofen (Primary)
  • Indications Irritability; Pervasive child development disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top